Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms
1 意见
administrator
07/29/23
Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.
显示更多
脸书评论
没有找到评论